Login to Your Account



Agios cues up PK-deficiency fighter AG-348 with first phase I test

By Michael Fitzhugh
Staff Writer

Friday, April 18, 2014

Agios Pharmaceuticals Inc. has started a phase I dosing study of its lead candidate for inborn errors of metabolism, AG-348. The experimental treatment for pyruvate kinase (PK) deficiency, a rare inherited metabolic disorder, could help rapidly advance the drug toward a proof-of-concept test in target patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription